ADCT 241
Alternative Names: ADCT-241; PSMA targeting antibody-drug conjugate - ADC TherapeuticsLatest Information Update: 29 Aug 2025
At a glance
- Originator ADC Therapeutics
- Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Aug 2025 ADC Therapeutics expects completion of an IND enabling activities of ADCT 241 by the end of 2025 in Switzerland
- 25 Apr 2025 Pharmacodynamics, adverse events and pharmacokinetics data from preclinical studies in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 13 Mar 2024 Preclinical trials in Solid tumours in Switzerland (Parenteral) before March 2024